Education
About Us
Working with TipRanks
Follow Us
Pacira Pharmaceuticals (PCRX)
NASDAQ:PCRX
Earnings Data
Report Date
May 06, 2026Before Open (Confirmed)
Period Ending
2026 (Q1)Consensus EPS Forecast
0.61Last Year’s EPS
0.62Same Quarter Last Year
Moderate Buy
Based on 6 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call conveys a broadly positive outlook: Pacira reported record gross margins, reinvigorated EXPAREL volume growth (~7% in Q4), expanded payer coverage (102M lives outside the bundle), strengthened IP (21 patents) and secured strategic partnerships (LG Chem, J&J). The company is investing in a promising pipeline (PCRX-201, PCRX-2002) and returned capital via buybacks while maintaining a healthy cash position ($238M). Offsetting items include rising R&D and SG&A (notably +56% R&D and +30% SG&A in Q4), revenue headwinds from buy-mix/discounting tied to a GPO, flat ZILRETTA sales, and near-term margin/inventory pressures. Overall, the positives (top-line momentum, margin expansion, IP runway, partnerships, and pipeline progress) outweigh the near-term cost and execution risks.Company Guidance
Record Revenue and Improved Margins
Fiscal 2025 total revenue of $726,000,000 and fourth-quarter consolidated non-GAAP gross margin improved to 80% (vs. 79% a year ago). Company reported highest gross margins in its history and is targeting a five-percentage-point margin improvement vs. 2024 (76% non-GAAP) by 2030.
EXPAREL Q4 Sales and Volume Growth
Fourth-quarter EXPAREL sales of $155.8M vs. $147.7M in Q4 2024 (~+5.5% revenue), with volume growth of approximately +7% year-over-year in Q4 driven by broader payer coverage and commercial initiatives.
Expanded Payer Coverage and Market Access
Ended 2025 with 102,000,000 lives covered for EXPAREL outside the surgical bundle (management noted this climbed to ~110,000,000 in early 2026), highlighting major commercial payer wins (Aetna, Cigna, TRICARE, Humana) and Medicare ASP+6% outpatient reimbursement.
Strategic Partnerships and Ex-U.S. Expansion
Signed major partnerships: LG Chem to commercialize EXPAREL in select Asia Pacific countries (South Korea, Thailand) with regulatory filings anticipated in 2026 and revenue expected to begin in 2027; J&J MedTech partnership now fully trained and expanding ZILRETTA reach in the U.S.
Strengthened IP and Litigation Outcome
Secured a volume-limited settlement with Fresenius providing EXPAREL runway visibility through 2039 and expanded IP estate to 21 patents across two families (up from a single patent at first Paragraph IV filing).
Progress on Pipeline with Near-Term Milestones
Advancing a data-rich phase: Phase II ASCEND Part A (PCRX-201) 52-week data expected end of year (49 patients enrolled); Part B to enroll ~90 patients starting midyear; interim analyses and top-line readouts for ZILRETTA shoulder OA and ioverao spasticity planned in 2026.
Cash Position and Shareholder Returns
Exited Q4 with $238,000,000 in cash and investments. Executed share repurchases (management referenced $150,000,000 of repurchases year-to-date, including $50,000,000 in Q4), retired ~2,000,000 shares and reduced outstanding shares to ~41,000,000; $150,000,000 remaining on buyback authorization.
Operational Manufacturing Improvements
Better-than-expected yields from new 200-liter EXPAREL facilities lowered per-unit costs and improved margins; management is adjusting production to hit inventory targets and expects steady margin increases via continuous improvement initiatives.
PCRX Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
PCRX Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Feb 26, 2026 | $22.59 | $21.91 | -3.01% |
Nov 06, 2025 | $21.10 | $22.05 | +4.50% |
Aug 05, 2025 | $22.54 | $22.40 | -0.62% |
May 08, 2025 | $24.91 | $25.12 | +0.84% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Pacira Pharmaceuticals (PCRX) report earnings?
Pacira Pharmaceuticals (PCRX) is schdueled to report earning on May 06, 2026, Before Open (Confirmed).
What is Pacira Pharmaceuticals (PCRX) earnings time?
Pacira Pharmaceuticals (PCRX) earnings time is at May 06, 2026, Before Open (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is PCRX EPS forecast?
PCRX EPS forecast for the fiscal quarter 2026 (Q1) is 0.61.